\n\t\t\tschemaVersion:\n\t\t\t<\/p>\n
CUSIP Number(s):<\/p>\n
45781K105<\/p>\n
1Names of Reporting Persons<\/p>\n
Novo Nordisk A\/S<\/p>\n
2Check the appropriate box if a member of a Group (see instructions)<\/p>\n
(a)
\n\t\t\t\t\t
(b)\n\t\t\t\t<\/p>\n
3Sec Use Only4Citizenship or Place of Organization<\/p>\n
\n\t\t\t\tDENMARK\n\t\t\t<\/p>\n
Number of Shares Beneficially Owned by Each Reporting Person With:5Sole Voting Power<\/p>\n
0.00<\/p>\n
6Shared Voting Power<\/p>\n
0.00<\/p>\n
7Sole Dispositive Power<\/p>\n
0.00<\/p>\n
8Shared Dispositive Power<\/p>\n
0.00<\/p>\n
9Aggregate Amount Beneficially Owned by Each Reporting Person<\/p>\n
0.00<\/p>\n
10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
\n\t\t\t\t11Percent of class represented by amount in row (9)<\/p>\n
0.00 % <\/p>\n
12Type of Reporting Person (See Instructions)<\/p>\n
CO<\/p>\n
Item 1. (a)Name of issuer:<\/p>\n
Innate Pharma SA<\/p>\n
(b)Address of issuer’s principal executive offices:<\/p>\n
117 Avenue de Luminy, BP 30191, Marseille, France, 13009<\/p>\n
Item 2. (a)Name of person filing:<\/p>\n
Novo Nordisk A\/S<\/p>\n
(b)Address or principal business office or, if none, residence:<\/p>\n
Novo Alle 1, DK-2880, Bagsvaerd Denmark<\/p>\n
(c)Citizenship:<\/p>\n
Denmark<\/p>\n
(d)Title of class of securities:<\/p>\n
Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)<\/p>\n
(e)CUSIP No.:<\/p>\n
45781K105<\/p>\n
Item 3.If this statement is filed pursuant to \u00a7\u00a7 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
\n\t\t\t\t\t(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
\n\t\t\t\t\t(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
\n\t\t\t\t\t(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
\n\t\t\t\t\t(e) An investment adviser in accordance with \u00a7 240.13d-1(b)(1)(ii)(E);
\n\t\t\t\t\t(f) An employee benefit plan or endowment fund in accordance with \u00a7 240.13d-1(b)(1)(ii)(F);
\n\t\t\t\t\t(g) A parent holding company or control person in accordance with \u00a7 240.13d-1(b)(1)(ii)(G);
\n\t\t\t\t\t(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
\n\t\t\t\t\t(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
\n\t\t\t\t\t(j) A non-U.S. institution in accordance with \u00a7 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with \u00a7 240.13d-1(b)(1)(ii)(J),
\n\t\t\t\t\t\t
please specify the type of institution:
\n\t\t\t\t\t(k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
\n\t\t\t\t\t Item 4.Ownership(a)Amount beneficially owned:<\/p>\n
0<\/p>\n
(b)Percent of class:<\/p>\n
0.00%<\/p>\n
(c)Number of shares as to which the person has:
\n\t\t\t\t\t
(i) Sole power to vote or to direct the vote:<\/p>\n
0<\/p>\n
(ii) Shared power to vote or to direct the vote:<\/p>\n
0<\/p>\n
(iii) Sole power to dispose or to direct the disposition of:<\/p>\n
0<\/p>\n
(iv) Shared power to dispose or to direct the disposition of:<\/p>\n
0<\/p>\n
Item 6.Ownership of more than 5 Percent on Behalf of Another Person. <\/p>\n
\n\t\t\t\t\t\t\tNot Applicable\n\t\t\t\t\t\t<\/p>\n
Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. <\/p>\n
\n\t\t\t\t\t\t\t\tNot Applicable\n\t\t\t\t\t\t\t<\/p>\n
Item 8.Identification and Classification of Members of the Group. <\/p>\n
\n\t\t\t\t\t\t\t\t\tNot Applicable\n\t\t\t\t\t\t\t\t<\/p>\n
Item 9.Notice of Dissolution of Group. <\/p>\n
\n\t\t\t\t\t\t\t\t\tNot Applicable\n\t\t\t\t\t\t\t\t<\/p>\n
Item 10.Certifications: <\/p>\n
\n\t\t\t\t\t\t\t\t\tNot Applicable\n\t\t\t\t\t\t\t<\/p>\n
SIGNATURE
\n\t\t\t\t\t\tAfter reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
\n\t\t\t\t\t\t Signature:\/s\/ Karsten Munk KnudsenName\/Title:Karsten Munk Knudsen, Chief Financial OfficerDate:06\/22\/2026<\/p>\n","protected":false},"excerpt":{"rendered":"schemaVersion: CUSIP Number(s): 45781K105 1Names of Reporting Persons Novo Nordisk A\/S 2Check the appropriate box if a member…\n","protected":false},"author":2,"featured_media":113815,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[44301,56987,56984,56985,272,56986],"class_list":["post-113814","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-amendment","tag-beneficial-ownership","tag-innate-pharma","tag-ipha","tag-novo-nordisk","tag-schedule-13g-a"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116794129513448434","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/113814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=113814"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/113814\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/113815"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=113814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=113814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=113814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}